Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Esperion Therapeutics reported quarterly earnings of $0.34 per share, beating estimates by 525%. - Revenue for the quarter ended March 2024 was $137.74 million, surpassing estimates by 159.32%. - The company has surpassed consensus EPS estimates four times in the last four quarters. - The stock has lost 29.1% since the beginning of the year, underperforming the S&P 500. Price Impact Rating: Bullish Impact Horizon Rating: Short-term Type: Earnings
- Esperion Therapeutics reported quarterly earnings of $0.34 per share, beating estimates by 525%.
- Revenue for the quarter ended March 2024 was $137.74 million, surpassing estimates by 159.32%.
- The company has surpassed consensus EPS estimates four times in the last four quarters.
- The stock has lost 29.1% since the beginning of the year, underperforming the S&P 500.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.